These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 30305449)

  • 41. The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis.
    Sarkar SK; Willson AML; Jordan MA
    J Immunol Res; 2024; 2024():5383099. PubMed ID: 38213874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disease phenotype prediction in multiple sclerosis.
    Herman S; Arvidsson McShane S; Zjukovskaja C; Khoonsari PE; Svenningsson A; Burman J; Spjuth O; Kultima K
    iScience; 2023 Jun; 26(6):106906. PubMed ID: 37332601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis.
    Burman J; Zjukovskaja C; Svenningsson A; Freyhult E; Wiberg A; Kultima K
    Brain Commun; 2023; 5(1):fcad011. PubMed ID: 36756308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrathecal Rituximab as a Rescue Therapy in Refractory Pure CSF Positive, Non-Teratomatous Type Anti-NMDAR Encephalitis.
    Krishnan P; Thomas K
    Ann Indian Acad Neurol; 2022; 25(5):925-927. PubMed ID: 36561001
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment.
    Jayaraman S; Jayaraman A
    Front Neurol; 2022; 13():980758. PubMed ID: 36313502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    Alcalá C; Quintanilla-Bordás C; Gascón F; Sempere ÁP; Navarro L; Carcelén-Gadea M; Landete L; Mallada J; Cañizares E; Belenguer A; Carratalá S; Domínguez JA; Pérez-Miralles FC; Gil-Perotín S; Gasqué R; Cubas L; Castillo J; Casanova B
    J Neurol; 2022 Jul; 269(7):3676-3681. PubMed ID: 35107597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody Therapies in Autoimmune Encephalitis.
    Smets I; Titulaer MJ
    Neurotherapeutics; 2022 Apr; 19(3):823-831. PubMed ID: 35060089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis?
    Gupta S; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34001659
    [No Abstract]   [Full Text] [Related]  

  • 50. A review of possible therapies for multiple sclerosis.
    Li H; Lian G; Wang G; Yin Q; Su Z
    Mol Cell Biochem; 2021 Sep; 476(9):3261-3270. PubMed ID: 33886059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition.
    Bhargava P; Kim S; Reyes AA; Grenningloh R; Boschert U; Absinta M; Pardo C; Van Zijl P; Zhang J; Calabresi PA
    Brain; 2021 Jun; 144(5):1396-1408. PubMed ID: 33724342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.
    Piehl F
    J Intern Med; 2021 Jun; 289(6):771-791. PubMed ID: 33258193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of B Cells in Multiple Sclerosis and Related Disorders.
    Comi G; Bar-Or A; Lassmann H; Uccelli A; Hartung HP; Montalban X; Sørensen PS; Hohlfeld R; Hauser SL;
    Ann Neurol; 2021 Jan; 89(1):13-23. PubMed ID: 33091175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    Bergman J; Burman J; Bergenheim T; Svenningsson A
    J Neurol; 2021 Feb; 268(2):651-657. PubMed ID: 32901316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.
    Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
    Fluids Barriers CNS; 2020 Jul; 17(1):49. PubMed ID: 32727487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Ocrelizumab for treatment of multiple sclerosis].
    Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP
    Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurofilaments in progressive multiple sclerosis: a systematic review.
    Williams T; Zetterberg H; Chataway J
    J Neurol; 2021 Sep; 268(9):3212-3222. PubMed ID: 32447549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Interventions towards Multiple Sclerosis Treatment.
    Metaxakis A; Petratou D; Tavernarakis N
    Brain Sci; 2020 May; 10(5):. PubMed ID: 32429225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab Prevents the Development of Experimental Autoimmune Encephalomyelitis (EAE): Comparison with Prophylactic, Therapeutic or Combinational Regimens.
    Al-Ani MR; Raju TK; Hachim MY; Hachim IY; Elemam NM; Guimei M; Bendardaf R; Maghazachi AA
    J Inflamm Res; 2020; 13():151-164. PubMed ID: 32214838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
    Sellebjerg F; Blinkenberg M; Sorensen PS
    CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.